<DOC>
	<DOCNO>NCT01305252</DOCNO>
	<brief_summary>The Study Hypothesis : Aggressive , upfront , dual therapy treatment-naïve NYHA I/II/III PAH superior traditional `` step-up '' approach . The study evaluate : 1 . Impact dual , upfront , therapy cardiovascular parameter PAH gauge cardiac magnetic resonance imaging ( cMRI ) 24 week event free survival outcome 48 week . 2 . Value novel biomarkers ( NT-pro BNP , Mts1/S100A4 , insulin resistance ) cutting-edge image technology ( cardiac MRI ) new endpoint clinical trial PAH . 3 . Utility longer clinical trial design use combined clinical event time clinical worsening surrogate</brief_summary>
	<brief_title>A 48-week Study Effect Dual Therapy ( Inhaled Treprostinil Tadafafil ) Versus Monotherapy ( Tadalafil ) , 2 FDA Approved Pulmonary Hypertension Medications</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Inclusion criterion : 1 . Age 18 &lt; 75 year baseline visit . 2 . Diagnosis Idiopathic PAH , Heritable PAH ( include Hereditary Hemorrhagic Telangiectasia ) , Associated PAH ( include collagen vascular disorder , drug+toxin exposure , repair congenital heart disease repair &gt; 5 year , portopulmonary disease , human immunodeficiency virus ( HIV ) infection protease inhibitor ) . 3 . PAH treatment naïve include prostacycline , endothelin receptor antagonist , phosphodiesterase inhibitor within 12 month prior enrollment . 4 . Previous Right Heart Catheterization document : 1 . Mean PAP ; 25 mmHg . 2 . Pulmonary capillary wedge pressure &lt; 15 mmHg . 3 . Pulmonary Vascular Resistance ; 3.0 Wood unit 240 dynes/sec/cm5 5.6MW distance ; 150 &lt; 450 meter . 6. WHO functional class II III judge principal investigator . Exclusion criterion : 1 . Group II V pulmonary hypertension . 2 . PAH unrepaired congenital heart defect . 3 . Current prior PAH treatment within last 612 month include experimental PAH therapy ( include limit tyrosine kinase inhibitor , rhokinase inhibitor , phosphodiesterase inhibitor , prostacycline , cGMP modulators ) . 4 . TLC &lt; 60 % predict ; TLC b/w 60 70 % predict , high resolution compute tomography must available exclude significant interstitial lung disease . 5 . FEV1 / FVC &lt; 70 % predict FEV1 &lt; 60 % predict 6 . Significant leftsided heart disease ( base pretrial Echocardiogram ) : 1 . Significant aortic mitral valve disease 2 . Diastolic dysfunction ; Grade II C.LV systolic function &lt; 45 % d. Pericardial constriction e. Restrictive cardiomyopathy f. Significant coronary disease demonstrable ischemia 7 . Chronic renal insufficiency define estimate creatinine clearance &lt; 30 ml/min ( MDRD equation ) 8 . Current atrial arrhythmia 9 . Uncontrolled systemic hypertension : SBP &gt; 160 mm DBP &gt; 100mm 10 . Severe hypotension : SBP &lt; 80 mmHg . 11 . Pregnant breastfeed 12 . Psychiatric , addictive , disorder compromise patient 's ability provide inform consent , follow study protocol , adhere treatment instruction 13 . Comorbid condition would impair patient 's exercise performance ability ass WHO functional class , include limited chronic lowback pain peripheral musculoskeletal problem . 14 . Contraindications magnetic resonance imaging , include significant claustrophobia , implant metallic object , others per Appendix X ) . 15 . Known allergy treprostinil tadalafil . 16 . Active oral nitrate use . 17 . Diabetes mellitus . 18 . Planned initiation cardiac pulmonary rehabilitation period study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>